Skip to main content
Figure 2 | BMC Pharmacology

Figure 2

From: The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution

Figure 2

Growth inhibition by RPR-130401 in asynchronously growing HCT-116, A-549 and MiAPaCa-2 cells. Mid-log phase cells were seeded (2 × 105 cells in 25 cm2 flasks) and incubated for 24-h prior to introduction of RPR-130401. The drug was present for up to the time of trypsinization and cell scoring. RPR-130401 induced a pronounced lengthening of the cell doubling time, namely, for HCT-116 cells, 23-h (50 nM drug = 1 × IC50) or 30-h (500 nM drug) vs. 18-h in drug-free controls; for A-549 cells, 30-h (0.71 μM drug = 1 × IC50) or 35-h (7.1 μM drug) vs. 22-h in drug-free controls; for MiAPaCa- 2 cells, 35-h (0.12 μM drug = 1 × IC50) or 40-h (1.2 μM drug) vs. 23-h in drug-free controls.

Back to article page

BMC Pharmacology

ISSN: 1471-2210